AstraZeneca posted its third-quarter and nine-month figures well before market open that day. These revealed that the company ...

Q3 2025 Earnings Call Transcript November 6, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.19, ...

AstraZeneca PLC (AZN) reports an 11% revenue increase, driven by oncology and biopharmaceuticals, while navigating R&D ...

AstraZeneca Pharma India reported a robust second quarter, with profit rising 41% year-on-year to ₹54.2 crore and revenue up 37%.

Acknowledging China’s innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is confident about further investing in the country, and working with local ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

On Friday, AstraZeneca ADRAZN reached a noteworthy performance benchmark, seeing its Relative Strength (RS) Rating jump into ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.

Anglo-Swedish pharma major AstraZeneca closed Thursday’s trading 3% higher, as investors digested its third quarter financial ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.